Invizyne Technologies INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
eXoZymes Inc. has successfully closed a public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds.
eXoZymes Inc. announced the pricing of its public offering of units, comprising common stock and warrants, expected to raise approximately $5.33 million.
eXoZymes Inc. has filed an 8-K detailing an investor presentation for a proposed public offering of securities.
eXoZymes Inc. has released an investor presentation on April 10, 2026, detailing information for potential underwriters and offering participants regarding a proposed securities offering.
EXOZYMES INC. filed an 8-K announcing an updated Investor Presentation related to its NCTx business as of March 30, 2026.
eXoZymes Inc. announced a successful 100-fold scale-up of N-trans-caffeoyltyramine (NCT) production with over 99% feedstock conversion using its proprietary exozyme platform.
EXOZYMES Inc. filed an 8-K announcing an updated investor presentation focusing on its NCTx business.
ExoZymes Inc. announced the filing of an updated investor presentation with the SEC as of September 30, 2025.
ExoZymes Inc. shareholders approved all management proposals at their 2025 Annual Meeting, including director elections, executive compensation, and a new equity plan.
ExoZymes Inc. announced the filing of an updated Investor Presentation with the U.S. Securities and Exchange Commission on July 7, 2025.
eXoZymes Inc. has been selected as a core industrial partner in the $9.2 million Meta-PURE initiative, a National Science Foundation-funded project aimed at advancing modular cell-free biomanufacturing.
EXOZYMES Inc. announced a significant increase in CEO Michael Heltzen's compensation, including a higher base salary, a substantial stock option grant, and a one-time bonus.
eXoZymes Inc. has appointed Damien Perriman as its Chief Commercial Officer to spearhead commercialization efforts for its AI-engineered enzyme technology.
eXoZymes Inc. (NASDAQ: EXOZ) announced an update on its operations through fiscal year 2024, highlighting its focus on commercialization via spin-outs, joint ventures, and licensing deals, as well as advancements in AI-driven enzyme development.
8-K: eXoZymes Inc. Announces Leadership Changes: Hayat Resigns, Rayo Appointed, Marlett Named Chairman
Mohammad Hayat resigned from his positions as Director, President, and Chairman of the Board of eXoZymes Inc., with Edgardo Rayo appointed as a new director and Christopher A. Marlett appointed as the new Chairman of the Board, all effective February 17, 2025.
Invizyne Technologies Inc. officially changed its name to eXoZymes Inc. on February 10, 2025, following the filing of a certificate of amendment to its articles of incorporation.
8-K: Invizyne Technologies Completes $15 Million Initial Public Offering, Shares Begin Trading on Nasdaq
Invizyne Technologies successfully completed its initial public offering, raising $15 million and commencing trading on the Nasdaq Capital Market under the ticker symbol IZTC.